Orthonika closed a second round of investment of £0.7MM (~US $0.91MM). Funds will support development of MenisciKnit™, a novel synthetic total knee meniscus replacement, specifically biomechanical testing and a preclinical pilot trial.
Funding comprised contributions from angel investors, plus a Biomedical Catalyst award and an Industrial Challenge award.
Other technologies in the meniscal replacement market include Active Implants’ NUsurface® polymer-based investigational treatment for persistent knee pain following medial meniscus surgery, Novopedics Meniscofix™ and Stryker’s FDA-approved CMI® collagen meniscus implant (acquired with purchase of Ivy Sports Medicine).
Orthonika closed a second round of investment of £0.7MM (~US $0.91MM). Funds will support development of MenisciKnit™, a novel synthetic total knee meniscus replacement, specifically biomechanical testing and a preclinical pilot trial.
Funding comprised contributions from angel investors, plus a Biomedical Catalyst award and an Industrial...
Orthonika closed a second round of investment of £0.7MM (~US $0.91MM). Funds will support development of MenisciKnit™, a novel synthetic total knee meniscus replacement, specifically biomechanical testing and a preclinical pilot trial.
Funding comprised contributions from angel investors, plus a Biomedical Catalyst award and an Industrial Challenge award.
Other technologies in the meniscal replacement market include Active Implants’ NUsurface® polymer-based investigational treatment for persistent knee pain following medial meniscus surgery, Novopedics Meniscofix™ and Stryker’s FDA-approved CMI® collagen meniscus implant (acquired with purchase of Ivy Sports Medicine).
Copy to clipboard 
